期刊文献+

LC-MS/MS测定马来酸桂哌齐特原料合成中间体残留 被引量:2

Determination of the Synthesized Intermediates Residual of Cinepazide Maleate by LC-MS/MS
原文传递
导出
摘要 目的采用LC-MS/MS测定马来酸桂哌齐特原料中间体氯乙酰吡咯烷、1-哌嗪乙酰基吡咯烷的含量,考察马来酸桂哌齐特原料中两种中间体残留情况。方法建立LC-MS/MS测定中间体氯乙酰吡咯烷、1-哌嗪乙酰基吡咯烷的方法,测定马来酸桂哌齐特原料样品中的中间体杂质残留。结果 LC-MS/MS测定中间体氯乙酰吡咯烷、1-哌嗪乙酰基吡咯方法精密度分别为3.6%和4.0%,线性回归方程分别为Y=26 501X 6 034(r=0.999 8,n=5)及Y=51 616X 10 434(r=0.999 9,n=5),平均回收率分别为98.2%和97.3%,测定马来酸桂哌齐特原料中两中间体均<0.05%。结论该方法准确可靠,灵敏度高,可为马来酸桂哌齐特原料质量控制及质量标准的建立提供依据。 OBJECTIVE To determine the content of chloroacetyl pyrrolidine and 1-piperazine acetyl pyrrolidine which are the intermediates of cinepazide maleate synthesis in cinepazide maleate by LC-MS/MS. METHODS The LC-MS/MS method was established for determination of chloricacetyl pyrrolidine and 1-piperazine acetyl pyrrolidine. The residue of these two intermediates had been determined in cinepazide maleate. RESULTS The precision of the LC-MS/MS for chloroacetyl pyrrolidine and 1-piperazine acetyl pyrrolidine were 3.6% and 4.0%, the linear regression equation were Y=26 501X-6 034 (r=0.999 8, n=5) and Y=51 616X-10 434(r=0.999 9, n=5), the average recoveries were 98.2% and 97.3%. The contents of two intermediates in cinepazide maleate were both less than 0.05%. CONCLUSION The method is accurate, reliable with high sensitivity, and can provide the basic to quality control and the establishment of quality standard for cinepazide maleate.
出处 《中国现代应用药学》 CAS CSCD 2013年第4期421-424,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 马来酸桂哌齐特 LC-MS MS 中间体 氯乙酰吡咯烷 1-哌嗪乙酰基吡咯烷 质量控制 cinepazide maleate LC-MS/MS intermediates chloroacetyl pyrrolidine 1-piperazine acetyl pyrrolidine quality control
  • 相关文献

参考文献4

  • 1GAO J H. Synthesis method of cinepazide maleate: China,1631877 (A) [P]. 2005-06-29.
  • 2WANG S J, YANG Z, ZHANG TJ, et al. Synthesis ofcinepazide maleate [J].中国药物化学杂志,2010,20(14): 278-281.
  • 3CLAUDE P F, GUY M R, BERNARD M P, et al. Derivativesof 1 -(3,4,5-trimethoxy cinnamoyl)-piperazine and process fortheir preparation: US, 3634411 [P]. 1971-1-11.
  • 4Ch.P(2010)VolII(中国药典 2010 年版.二部)[S]. 2010:608-609.

共引文献1

同被引文献27

  • 1沈迈春,姜爱东,徐敏,姚卫.1-(3-氯苯基)-4-(3-氯丙基)哌嗪盐酸盐的合成[J].精细化工中间体,2005,35(5):24-25. 被引量:7
  • 2董新荣,杨建奎,李霞,刘仲华.盐酸奈法唑酮的合成[J].化学研究,2006,17(4):48-50. 被引量:3
  • 3ICH.Guideline:Impurities in New Drug Substances Q3A (R2).[EB/OL](2006-10-25)[2013-3-20].http://www.gmp-compliance.org/guidemgr/files/ICH%20Q3A%20R2.PDF.
  • 4ICH.Guideline:Impurities in New Drug Products Q3B,(R2).[EB/OL](2006-10-25)[2013-3-20].http://www.gmp-compliance.org/guidemgr/files/273899EN.PDF.
  • 5CHMP.Guideline on the Limits of Genotoxic Impurities.[EB/OL](2006-06-28)[2013-3-20].http://www.gmp-compliance.org/guidemgr/files/519902EN.PDF.
  • 6CDER.Guidance for Industry Genotoxic and Carcinogenic Impurities in Drug Substances and Products:Recommended Approaches.[EB/OL](2008-10)[2013-3-20].http://www.fda.gov/cder/guidance/index.htm.
  • 7Kakadiya PR,Reddy BP,Singh V,et al.Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavia and Ritonavia Active phaemaceutical ingredients by LC/MS/MS using electrospray ionization[J].J Pharm Biomed Anal,2011,55(2):379-84.
  • 8http://potency.berkeley.edu.
  • 9Richard E Young.Trace Analysis of Volatile and semi-Volatile Genotoxic Impurities in drug substances and Drug Products at Roche Palo Alto[EB/OL](2009-11-24)[2013-3-20].
  • 10Müller L,Mauthe R J,Riley C M,et al.A rational fordetermining,testing,and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity[J].Regul Toxicol Pharmacol,2006,44(3):198-211.

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部